Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;20(6):373-385.
doi: 10.1038/s41569-022-00823-5. Epub 2023 Jan 10.

Macrophages in cardiac remodelling after myocardial infarction

Affiliations
Review

Macrophages in cardiac remodelling after myocardial infarction

Jonathan Yap et al. Nat Rev Cardiol. 2023 Jun.

Abstract

Myocardial infarction (MI), as a result of thrombosis or vascular occlusion, is the most prevalent cause of morbidity and mortality among all cardiovascular diseases. The devastating consequences of MI are compounded by the complexities of cellular functions involved in the initiation and resolution of early-onset inflammation and the longer-term effects related to scar formation. The resultant tissue damage can occur as early as 1 h after MI and activates inflammatory signalling pathways to elicit an immune response. Macrophages are one of the most active cell types during all stages after MI, including the cardioprotective, inflammatory and tissue repair phases. In this Review, we describe the phenotypes of cardiac macrophage involved in MI and their cardioprotective functions. A specific subset of macrophages called resident cardiac macrophages (RCMs) are derived from yolk sac progenitor cells and are maintained as a self-renewing population, although their numbers decrease with age. We explore sophisticated sequencing techniques that demonstrate the cardioprotective properties of this cardiac macrophage phenotype. Furthermore, we discuss the interactions between cardiac macrophages and other important cell types involved in the pathology and resolution of inflammation after MI. We summarize new and promising therapeutic approaches that target macrophage-mediated inflammation and the cardioprotective properties of RCMs after MI. Finally, we discuss future directions for the study of RCMs in MI and cardiovascular health in general.

PubMed Disclaimer

References

    1. Benjamin, E. J. et al. Heart disease and stroke statistics — 2019 update: a report from the American Heart Association. Circulation 139, e56–e528 (2019). - DOI - PubMed
    1. Nowbar, A. N., Gitto, M., Howard, J. P., Francis, D. P. & Al-Lamee, R. Mortality from ischemic heart disease. Circ. Cardiovasc. Qual. Outcomes 12, e005375 (2019). - DOI - PubMed - PMC
    1. Ambrose, J. A. & Dangas, G. Unstable angina: current concepts of pathogenesis and treatment. Arch. Intern. Med. 160, 25–37 (2000). - DOI - PubMed
    1. Newby, D. E. & Fox, K. A. A. Unstable angina: the first 48 hours and later in-hospital management. Br. Med. Bull. 59, 69–87 (2001). - DOI - PubMed
    1. Braunwald, E. Unstable angina and non-ST elevation myocardial infarction. Am. J. Respir. Crit. Care Med. 185, 924–932 (2012). - DOI - PubMed

LinkOut - more resources